

CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

July 15, 2025

To

**BSE Limited**

Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal  
Street, Mumbai – 400 001

**The National Stock Exchange of India Ltd**

Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Clarification on Volume Movement**

**Ref: BSE Limited email dated July 15, 2025 (L/SURV/ONL/PV/NS/2025-2026/267)**

We refer to the afore-mentioned email seeking clarification on the significant increase in volume of our security across exchanges, in the recent past.

We would like to reiterate that our Company has been disclosing and will continue to disclose all the necessary information's/disclosures in accordance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations") within the stipulated timelines and has not withheld any material information/ event that in our opinion would have a bearing on the volume behavior in our scrip.

Further, we request you to note that the equity shares of the Company are freely traded on the Stock Exchanges and the Company will not be in a position to comment on the significant increase in volume of our security across exchanges.

We would like to reiterate that our Company is committed to compliance with the SEBI Listing Regulations and any information, likely to have bearing on the volume of the share would be disclosed to the stock exchanges from time to time.

This is for your information and records.

Thanking you

Yours Sincerely,

For **Neuland Laboratories Limited**

**Sarada Bhamidipati**

**Company Secretary**